Eylea (aflibercept) is a protein pharmaceutical. Aflibercept was first approved as Eylea on 2011-11-18. It is used to treat diabetic retinopathy and macular edema in the USA. It has been approved in Europe to treat colorectal neoplasms, diabetes complications, macular edema, and wet macular degeneration. The pharmaceutical is active against vascular endothelial growth factor A and placenta growth factor. In addition, it is known to target vascular endothelial growth factor B.
|Indication||colorectal neoplasms, diabetes complications, diabetic retinopathy, macular edema, wet macular degeneration|
|Drug Class||Receptor molecules, native or modified: vascular endothelial growth factor (VEGF) receptors|